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Abstract
Background: It has been demonstrated that acute oral administration of schisandrin B (Sch B), an active
dibenzocyclooctadiene isolated from Schisandrae Fructus (a commonly used traditional Chinese herb), increased
serum and hepatic triglyceride (TG) levels and hepatic mass in mice. The present study aimed to investigate the
biochemical mechanism underlying the Sch B-induced hypertriglyceridemia, hepatic steatosis and hepatomegaly.
Methods: Male ICR mice were given a single oral dose of Sch B (0.25–2 g/kg). Sch B-induced changes in serum
levels of biomarkers, such as TG, total cholesterol (TC), apolipoprotein B48 (ApoB 48), very-low-density lipoprotein
(VLDL), non-esterified fatty acid (NEFA) and hepatic growth factor (HGF), as well as hepatic lipids and mass, epididymal
adipose tissue (EAT) and adipocyte size, and histological changes of the liver and EAT were examined over a period of
12–120 h after Sch B treatment.
Results: Serum and hepatic TG levels were increased by 1.0–4.3 fold and 40–158% at 12–72 h and 12–96 h, respectively,
after Sch B administration. Sch B treatment elevated serum ApoB 48 level (up to 12%), a marker of exogenous TG, but
not VLDL, as compared with the vehicle treatment. Treatment with Sch B caused a time-/dose-dependent reduction in
EAT index (up to 39%) and adipocyte size (up to 67%) and elevation in serum NEFA level (up to 55%). Sch B treatment
induced hepatic steatosis in a time-/dose-dependent manner, as indicated by increases in total vacuole area (up to 3.2
fold vs. the vehicle control) and lipid positive staining area (up to 17.5 × 103 μm2) in liver tissue. Hepatic index and serum
HGF levels were increased by 18–60% and 42–71% at 12–120 h and 24–72 h post-Sch B dosing, respectively. In addition,
ultrastructural changes, such as increase in size and disruption of cristae, in hepatic mitochondria were observed in Sch
B-treated mice.
Conclusion: Our findings suggest that exogenous sources of TG and the breakdown of fat storage in the body
contribute to Sch B-induced hypertriglyceridemia and hepatic steatosis in mice. Hepatomegaly (a probable
hepatotoxic action) caused by Sch B may result from the fat accumulation and mitochondrial damage in liver
tissue.
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Background
Primary or secondary hyperlipidemia featuring raised
serum triglycerides (TG) either alone or combined with
elevated serum low density lipoprotein (LDL)-cholesterol
or low serum LDL-cholesterol concentrations has a high
prevalence in developing and developed countries [1]. It is
commonly associated with a set of metabolic abnormal-
ities, such as central obesity, type 2 diabetes, and coronary
heart disease [2–4]. In addition, patients with severe
hypertriglyceridemia also have increased incidences in cer-
tain diseases such acute pancreatitis [5], chronic periodon-
titis [6] and schizophrenia [7]. Furthermore, high blood
level of TG may cause nonalcoholic fatty liver disease
(NAFLD), a common chronic liver disorder which is caus-
ally related to the development of hepatic steatosis and
cirrhosis [8] as well as the increased cardiovascular risk
(CVR) [9]. In view of adverse health consequences associ-
ated with hypertriglyceridemia secondary to hepatic stea-
tosis, the search for lipid-lowering drugs has been an area
of intensive research. In this connection, the pathophysi-
ology of hypertriglyceridemia is complex, involving the
overproduction of hepatic very low density lipoprotein
(VLDL) and intestinal chylomicron (CM), dysfunctional
peripheral lipolysis, and impaired clearance of TG-
enriched remnant lipoproteins [10]. The biochemical
mechanism underlying hypertriglyceridemia in relation to
other organs/tissues remains relatively unclear. The un-
derstanding of pathophysiological processes that lead to
the metabolic disturbances associated with hypertriglyc-
eridemia can open up avenues for the development of
lipid-lowering drugs which act on novel targets.
Schisandrin B (Sch B) is the most abundant active lig-
noid component in Schisandrae Fructus, a commonly
used herb in Chinese medicine. Pharmacological studies
on schisandrin B have revealed a wide spectrum of bio-
logical activities particularly those related to liver func-
tions (including lipid metabolism). Up to know, Sch B has
been shown to produce anti-inflammatory [11, 12], cardi-
oprotective [13, 14], hepatoprotective [15, 16], and anti-
cancer actions [17, 18] in vivo and in vitro. However, the
use of Schisandrae Fructus and its active components is
more popular in China and other Asian countries which
are strongly influenced by the practice of Chinese medi-
cine. Previous studies from our laboratory have demon-
strated that Sch B treatment increased serum and hepatic
TG levels, serum alanine aminotransferase (ALT) activity
and hepatic mass in mice, suggestive of a mouse model of
hypertriglyceridemia combined with hepatic steatosis and
injury [19–21]. It is well known that TG in bloodstream is
derived from exogenous (dietary sources) and endogenous
(synthesis in liver using fatty acids) pathways. However,
the biochemical processes involved in the Sch B-induced
changes in TG metabolism remains unclear. In the
present study, we endeavored to elucidate the biochemical




Sch B was purified from the petroleum ether extract of
dried SF by silica gel column chromatography as previ-
ously described [22]. The purity of Sch B, as determined
by high performance liquid chromatography analysis,
was higher than 95%. Betis extra virgin olive oil was pur-
chased from a local market. Assay kit for TG (certificate
number 135991) and total cholesterol (TC) (certificate
number 135991) were purchased from Zhongsheng
Beikong Biotechnology Science Inc. (Beijing, People’s Re-
public of China). Assay kits for serum apolipoprotein
B48 (Apo B48, certificate number F20030794), very-low-
density lipoprotein (VLDL, certificate number E11030776)
and hepatocyte growth factor (HGF, certificate number
H03030777) were bought from Cusabio Biotech (Wuhan,
China). Assay kit for non-esterified fatty acid (NEFA, cer-
tificate number 20150130.40030) was purchased from
Rigor Bioscience Development LTD (Beijing, China).
Animal treatment
Male Institute of Cancer Research (ICR) mice (Grade II,
certificate number 118, SCXK [jing] 2006–0009), weighing
18–20 g, were purchased from the Vital River Laboratory
Animal Technology Co., Ltd. (Beijing, People’s Republic of
China). They were maintained at 20–21 °C, with a relative
humidity of 50–55% and allowed free access to water and
food. Animals were housed ten in each cage, and ten mice
were assigned to each group. Experiments were performed
when the animals had attained a body weight of 25–28 g.
All experimental procedures were approved by the Uni-
versity Committee on Research Practice in Beijing Univer-
sity of Chinese Medicine.
Experimental design
Design one
In this study, the time response of Sch B-induced
changes in serum TG, TC, NEFA, Apo B48, VLDL, and
HGF levels, as well as hepatic steatosis were investigated.
In addition, histopathological changes of liver and adi-
pose tissues were also examined. Mice were orally
treated with Sch B (1 g/kg) suspended in olive oil. The
dose of Sch B was chosen with reference to our previous
studies. Control animals were orally administered the ve-
hicle (ie, olive oil 5 mL/kg) only. After 12, 24, 48, 72, 96,
and 120 h post-dosing, mice were sacrificed under light
ether anesthesia. Blood samples were collected from the
orbital vein, liver and adipose tissue samples were also
obtained and subjected to biochemical analysis and
histological examination.
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Design two
This study was designed to investigate the dose response
of Sch B-induced changes in parameters described
above. Mice were orally administered with Sch B at in-
creasing doses of 0.25, 0.5, 1, and 2 g/kg, suspended in
olive oil. Control (ie, non-Sch B-treated) animals were
given the vehicle. Mice were sacrificed at 24 or 48 h
after Sch B treatment.
Biochemical analysis
Serum samples were prepared by centrifuging the whole
blood for 8 min at 2,000 × g and stored at−70 °C until
used for biochemical analysis. Liver tissue samples were
homogenized in 9 volumes of saline using two 10-s
bursts of a tissue disintegrator at 13,500 rpm, and the
homogenate was then centrifuged at 2,000 × g for
15 min to obtain the supernatants. Hepatic supernatant
(30 μL) and serum (10 μL) were used to determine TG
levels using the GPO-PAP (glycerol-3-phosphate oxidase
and phenol + aminophenazone) method. Serum NEFA
level was measured by automatic Biochemistry Analyzer
(Beckman coulter Synchron CX4 PRO, Brea, CA, USA).
Serum Apo B48, VLDL and HGF levels were determined
using enzyme-linked immunosorbent assay (ELISA) with
polyclonal antibodies according to the manufacturer’s
instructions.
Hematoxylin and eosin (HE) staining
A small block of adipose tissue was dissected from the
left epididymis, which was fixed in 10% neutral buffered
formalin and then embedded in paraffin. The paraffin
block was cut into 5 μM thick slices, and they were
stained with hematoxylin and eosin, according to the
manufacturer’s protocol. Representative areas were
photographed under the viewing of a Nikon 90i micro-
scope (Nikon, Tokyo, Japan) at a magnification of 20×.
The average surface area of 10 adipocytes in each slice
section was analyzed with Image-Pro Plus 6.0 software
(Media Cybernetics Inc. USA). The same procedures
were performed for samples prepared from liver tissues.
Five images of hepatic lobules in each liver tissue slice
were quantified by an observer that was blinded to the
experimental design, and the total area of vacuoles in
each slice was also computed by Image-Pro Plus 6.0
software.
Oil Red O staining
Fresh liver tissue sample was frozen and cut into frozen
slices at 6 μM thickness. They were stained with a fil-
tered solution of 1% Oil Red O (Sigma-Aldrich) in 60%
aqueous triethylphosphate for 15 min, followed by rins-
ing with 60% isopropanol. The tissue slices were then
mounted in glycerin jelly, and five images were randomly
selected from each slice at a magnification of 200× for
the estimation of lipid positive staining area, using
Image-Pro Plus 6.0 software.
Trasmission electron microscopy (TEM)
For electron microscopy, the liver biopsy was rapidly cut
into small pieces which were transferred to the following
fixatives (pH 7.4) at 4 °C: a) 2% glutaraldehyde Soren-
sen’s phosphate buffer for 3 h; b) 1% OsO4 phosphate
buffer for 2 h, followed by washing with same buffer and
further incubated for 24–48 h in a refrigerator (4 °C).
Liver tissue sections were dehydrated with absolute etha-
nol and embedded in Epon 812. Observations were
made on 0.5-μm thick Epon sections from controls that
were stained with toluidine blue. After ultra-thin (600 Å)
sectioning by ultramicrotome, the sections were lightly
counter-stained with uranyl acetate and lead citrate and
were viewed under JEM-1230 electron microscope for
lipid inclusion in the cytoplasm of hepatocytes and the
morphology of mitochondria.
Measurement of hepatic/EAT index
The liver and epididymal adipose tissue (EAT) were ex-
cised and weighed. Hepatic or adiposity index was esti-
mated from the ratio of liver or adipose tissue weight to
body weight (liver or adipose tissue weight/body
weight × 100).
Statistical analysis
All values are expressed as means ± standard error of the
mean. Data were analyzed by one-way analysis of vari-
ance (ANOVA) using SPSS (version 16.0) statistical ana-
lysis program, and then differences among means were
determined using Dunnett’s multiple comparisons test
or post hoc analysis. Differences were considered signifi-
cant at P < 0.05. The parameters of Emax (maximal ef-
fect), KD (affinity), and pD2 (an index of affinity) were
obtained using the Scott’s plot method.
Results
Serum
Effects of Sch B treatment on serum TG and TC levels
Serum TG levels were elevated by 262, 427, 289, and 100%
at 12, 24, 48 and 72 h after Sch B (1 g/kg) treatment, re-
spectively, when compared with the control group (Fig. 1a).
Sch B dose-dependently increased serum TG levels by
147–268%, with values of Emax (5.19 mmol/L), KD
(0.82 mmol/kg) and pD2 (3.09) being estimated (Fig. 1b).
Serum TC concentrations in mice receiving Sch B at dose
of 1 g/kg were markedly increased by 13% (P < 0.05) and
21% (P < 0.01) at 24 and 48 h post treatment, respectively,
but it was decreased by 13% (P < 0.05) at 6 h post
dosing (Fig. 1c). Sch B (0.25–2 g/kg) treatment dose-
dependently increased serum TC levels (up to 17%),
with values of Emax, KD, and pD2 being estimated to
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be 3.82 mmol/L, 1.00 mmol/kg, and 3.00, respectively,
at 24 h post treatment (Fig. 1d).
Effects of Sch B treatment on serum Apo B48 and VLDL
levels
Serum Apo B48 and VLDL, which are involved in TG
transport and formation, respectively, were examined in
Sch B-treated mice. As shown in Fig. 2a, Sch B treat-
ment significantly increased serum Apo B48 levels by 7,
11, 12, 12, 10, and 10% at 12, 24, 48, 72, 96 and 120 h
post dosing (P < 0.01), respectively, when compared with
the control group. Sch B also markedly elevated serum
Apo B48 levels by 8–11% in a dose-dependent manner
(P < 0.01), with Emax (3926.8 ng/mL), KD (0.22 mmol/kg)
and pD2 (3.66) being estimated (Fig. 2b). Sch B markedly
decreased serum VLDL levels by 19% at 24 (P < 0.05)
and 48 (P < 0.01) h post treatment (Fig. 2c). Further-
more, Sch B (0.25 and 0.5 g/kg) significantly decreased
serum VLDL levels by 20 (P < 0.01) and 15% (P < 0.05),
respectively, at 24 h post treatment, but no detectable
changes were observed after dosing with Sch B at 1 and
2 g/kg, when compared with the control group (Fig. 2d).
Effects of Sch B treatment on serum NEFA and HGF levels
NEFA is mainly released from adipose tissue by lipolysis.
Figure 3a shows that Sch B (1 g/kg) significantly elevated
serum NEFA levels by 55, 37, 34, and 32% at 24, 48, 72,
and 96 h post dosing, respectively. Furthermore, Sch B
dose-dependently increased serum NEFA levels by ap-
proximately 59% at 24 h post-treatment (P < 0.01), with
values of Emax, KD and pD2 being estimated to be
545.4 μmol/L, 1.80 mmol/kg, and 2.74, respectively
(Fig. 3b). HGF, a polypeptide implicated in liver regener-
ation, was examined in Sch B-treated mice. Serum HGF
levels were increased by 71, 54, 54, and 42% (P < 0.05 or
P < 0.01) at 24, 48, 72 and 96 h post treatment with Sch
B, respectively (Fig. 3c). Sch B dose-dependently in-
creased serum HGF levels by 24–86% at 24 h post treat-
ment (p < 0.01), with the values for Emax, KD, and pD2
being estimated to be 219.95 mmol/L, 3.51 mmol/kg,
and 2.45, respectively (Fig. 3d).
Adipose tissue
Effects of Sch B treatment on EAT and adipocyte mass
Figure 4 shows that Sch B treatment reduced the EAT
mass in a time-/dose-dependent manner. Sch B (1 g/kg)
decreased the EAT index by 22, 24, 39, and 32% at 12,
24, 48 and 72 h post dosing, respectively (Fig. 4a). The
maximal effect of Sch B-induced degradation of EAT
was observed at 48 h post treatment. In addition, Sch B
(1 and 2 g/kg) significantly decreased the EAT index by
24 and 30%, respectively, at 24 h post-treatment, with
A B
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Fig. 1 Time/dose response of schisandrin B (Sch B) treatment on serum triglyceride (TG) and total cholesterol (TC) levels. Mice were orally administered
with Sch B (1 g/kg, suspended in olive oil). Control (untreated) animals received the vehicle (5 ml/kg) only. For the time course study, serum TG and TC
levels were measured at 12, 24, 48, 72, 96, and 120 h after Sch B treatment or 24 h post-vehicle treatment (a and c). Preliminary studies indicated that
vehicle-treated mice did not show any changes in serum lipids from 12 to 120 h post treatment. For the dose–response study, serum TG and TC were
determined at 24 h in the Sch B-treated mice. Pharmacodynamic parameters (b and d) Emax (maximal effect), KD (affinity), and pD2 (an index of affinity)
were estimated with the Scott’s plot method. Values given are the mean ± SEM, with n = 10. *P < 0.05, **P < 0.01 vs control, using a one-way ANOVA
followed by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
Zhang et al. Lipids in Health and Disease  (2017) 16:8 Page 4 of 15
values of Emax (0.47 mmol/kg), KD (2.15 mmol/kg) and
pD2 (2.67) being estimated (Fig. 4b). Histological exam-
ination of EAT section indicated that Sch B at 1 g/kg de-
creased the adipocyte size in a time-dependent manner.
As shown in Fig. 4c and d, the equivalent area of adipo-
cytes was significantly lowered by 43, 47, 67, 52, 16, and
12% at 12, 24, 48, 72, 96 and 120 h post-dosing with Sch
B (1 g/kg), respectively (P < 0.01). The maximal effect of
Sch B on the reduction of adipocyte mass was observed
at 48 h post treatment. Additionally, a restoration of
normal adipocyte morphology was observed at 120 h
after Sch B treatment (1 g/kg).
Liver
Effects of Sch B treatment on hepatic TG and TC contents
Figure 5a and b show that Sch B increased hepatic TG con-
tents in a time-/dose-dependent manner. Sch B (1 g/kg) in-
creased hepatic TG by 76, 114, 158, 112, and 40% at 12, 24,
48, 72, and 96 h post treatment, respectively. Sch B dose-
dependently increased hepatic TG contents by 71–111% at
24 h post-treatment, with values of Emax (23.64 μmol/g liver
tissue), KD (1.95 mmol/kg) and pD2 (2.71) being estimated.
Sch B increased hepatic TC contents by 26–53% (P < 0.01)
from 48 to 120 h post treatment. However, Sch B reduced
hepatic TC contents by 34% at 24 h post-treatment (Fig. 5c).
As Sch B treatment produced a biphasic effect on hepatic
TC levels, the values of Emax, KD, and pD2 were estimated
at 24 and 48 h post dosing. Sch B (0.25–2 g/kg) decreased
hepatic TC levels by 16–38% (P < 0.01) at 24 h post dosing,
with values of Emax (1.82 μmol/g liver tissue), KD
(0.69 mmol/kg) and pD2 (3.16) being estimated (Fig. 5d).
Hepatic TC content was elevated by 10–33% at 48 h post
treatment, with values of Emax, KD and pD2 being estimated
to be 6.37 μmol/g liver tissue, 0.19 mmol/kg, and 3.72, re-
spectively (Fig. 5e).
Effects of Sch B treatment on hepatic lipid accumulation
To confirm the effect of Sch B on lipid accumulation
in the liver, Oil red O staining was performed to dis-
tinguish and quantify the accrual of lipid deposits
(LD) in liver tissues. Administration with Sch B at
1 g/kg induced an accumulation of lipids in liver tis-
sue, as evidenced by the detection of an average of
10.4−, 17.5−, 12.5−, 4.8−, 1.6 × 103 μm2 of lipid posi-
tive staining area at 12, 24, 48, 72 and 96 h post dos-
ing, respectively (Fig. 6a and b). The maximum lipid
accumulation occurred at 24 h post treatment, which
was manifested as numerous large cytosolic lipid
droplets around the central vein. Furthermore, hepatic
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Fig. 2 Time/dose response of Sch B treatment on serum apolipoprotein B48 (Apo B48) and very-low-density lipoprotein (VLDL) levels. Experimental
details were described in Fig. 1. For the time course study, serum Apo 48 and VLDL levels were measured at 12, 24, 48, 72, 96, and 120 h after Sch B
treatment (a and c). For the dose–response study, mice were intragastrically treated with Sch B (0.25–2 g/kg). Twenty-four h later, serum samples were
obtained to determine the Apo B 48 and VLDL levels, as well as the Emax, KD, and pD2 values (b and d). Values given are the mean ± SEM, with n = 10.
*P < 0.05, **P < 0.01 vs Control, using a one-way ANOVA followed by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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with Sch B at 1 g/kg. In addition, Sch B (0.25–2 g/kg)
treatment caused hepatic steatosis, as indicated by
dose-dependent increases in lipid positive staining
area (2.6 × 103–31.2 × 103 μm2) (Fig. 7a and b).
Effects of Sch B treatment on hepatic mass and hepatocyte
structure
Figure 8 shows that Sch B treatment enhanced hep-
atic weight in a time-/dose-dependent manner. Sch
B increased hepatic index by 18–60% at 12–120 h
post treatment. The maximum effect of Sch B treat-
ment on hepatic index was observed at 48 h post
dosing (Fig. 8a). Sch B (0.25–2 g/kg) dose-
dependently increased hepatic index by 24–29% at
24 h post treatment, with values of Emax (7.58), KD
(0.15 mmol/kg) and pD2 (3.82) being estimated
(Fig. 8b). The liver tissue was stained with HE and
observed under an optical microscope (×200). It was
found that the structure of hepatic lobules was intact
in the control group, as characterized by the radiat-
ing arrangement of hepatic cells and cords around
the central vein, as well as clear and uniform Disse’s
spaces. In addition, hepatocytes were relatively large
in size and polygonic in shape, with rich cytoplasm
and large nuclei in the center without detectable
steatosis. However, Sch B treatment (1 g/kg) in-
creased hepatic lipid deposits, which appeared as
small vacuoles within the cytoplasm of liver cells at
12 h post treatment. Moreover, large numbers and
different sizes of circular vacuoles were observed in
the cytoplasm at 24 h post dosing with Sch B, fea-
turing macrovesicular steatosis and hepatocyte bal-
looning. The extent of hepatic steatosis was
gradually ameliorated from 48 h post treatment on-
wards, with the complete recovery observable at
120 h post treatment (Fig. 8c and d). Sch B treat-
ment (0.25–2 g/kg) dose-dependently increased the
total vacuole area in liver tissue by 169–380% (Fig. 9a
and b).
Effects of Sch B treatment on hepatocyte ultrastructure
Electron microscopic analysis indicated that Sch B
treatment (1 g/kg) induced ultrastructural abnormal-
ities in hepatic mitochondria, which was in associ-
ation with hepatic steatosis. In the control group,
there were numerous mitochondria of different shapes
and sizes in the cytoplasm, and their cristae were well de-
fined and arranged closely to one another. However, sparse
Time post-treatment (hour) Dose (g/kg)
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Fig. 3 Time/dose response of Sch B treatment on serum non-esterified fatty acid (NEFA) and hepatocyte growth factor (HGF) levels. Experimental details
were described in Fig. 1. For the time course study, serum NEFA and HGF levels were measured at 12, 24, 48, 72, 96 and 120 after Sch B treatment (a and
c). For the dose–response study, mice were intragastrically treated with Sch B (0.25–2 g/kg). Twenty-four 24 h later, the pharmacodynamic parameters (Emax,
KD, and pD2) were estimated (b and d). Values given are the mean ± SEM, with n = 10. *P< 0.05, **P< 0.01 vs Control, using a one-way ANOVA followed
by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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mitochondria which appeared swollen with disrupted cris-
tae, together with clear and abundant lipid droplets in he-
patocytes were observed at 72 h post-treatment with Sch B.
Morphological damage of mitochondria was found to be
recovered at 120 h post-dosing (Fig. 10).
Discussion
The synthesis of TG in humans mainly involves exogen-
ous and endogenous pathways. The exogenous pathway
starts with the intestinal absorption of TG from dietary



















































Fig. 4 Time/dose response of Sch B treatment on epididymal adipose tissue (EAT) and adipocyte mass. Experimental details were described in
Fig. 1. For the time course study, EAT index (EAT weight/body weight × 100) and adipocyte size were measured at 12, 24, 48, 72, 96, and 120 h
after Sch B treatment (a, b and d). A representative microscopic picture of a haematoxylin and eosin (HE)-stained EAT section for each group is
shown in (c). The adipocyte area of each section was computed by Image Proplus 6.0. For the dose–response study, mice were intragastrically treated with
Sch B (0.25–2 g/kg). Twenty-four h later, the pharmacodynamic parameters (Emax, KD, and pD2) of Sch B on EAT index were measured (b). Values given are
the mean ± SEM, with n= 10. *P< 0.05, **P< 0.01 vs Control, using a one-way ANOVA followed by Dunnett’s multiple comparisons test, Student’s t-test or
post-hoc analysis
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pathway, TG is synthesized using fatty acids in the liver
and it is carried by TG-rich VLDL into bloodstream
[24]. Therefore, TG in the blood mainly exists in the
form of CM and/or VLDL. In the present study, Sch B
treatment increased serum TG levels in a time-/dose-
dependent manner from 6 to 96 h post-dosing. However,
the serum TC level was elevated between 24 and 48 h
after Sch B treatment. Scott’s plot analysis showed that
the potency of Sch B-induced elevation in serum TG is
about 15.8-fold higher than that of TC. Moreover, no
significant changes were detected in serum HDL and
LDL levels at all time points following the administra-
tion of Sch B (data not shown). High blood TG levels in
both animals and humans result from either the sup-
pression of TG catabolic pathway or promotion of TG
synthetic pathway, or both. Results obtained from the
present study suggest that Sch B-induced hypertriglyc-
eridemia mainly involves exogenous pathway, as indi-
cated by a high level of serum Apo B 48 (a unique
marker of intestine-derived CM [25]) after Sch B treat-
ment. The present study adopted a high, single oral dose





























































































































Fig. 5 Time/dose response of Sch B treatment on hepatic triglyceride (TG) and total cholesterol (TC) contents. Experimental details were described in
Fig. 1. For the time course study, hepatic TG and TC contents were measured at 12, 24, 48, 72, 96, and 120 h after Sch B treatment (a and c). For the
dose–response study, mice were intragastrically treated with Sch B (0.25–2 g/kg). Twenty-four h and forty-eight h later, the pharmacodynamic parameters
Emax, KD, and pD2 were determined (b, d and e). Values given are the mean ± SEM, with n= 10. *P< 0.05, **P< 0.01 vs Control, using a one-way ANOVA
followed by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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doses used in other pharmacological studies in rodents)
in order to induce changes in lipid metabolism in vivo.
Presumably, the high dose of Sch B can elicit biological
responses in various tissues in a time-dependent manner
via specific signaling pathways.
Adipose tissue, an anatomical description for loose
connective tissue composed of adipocytes, also plays an
important role in lipid metabolism [26]. Adipocyte dys-
function may result in dysregulation of a wide range of
adipose tissue-derived secretory factors, referred to as
adipokines, which promote the release of NEFAs from
adipocytes into the blood stream. The NEFAs are then
delivered to the liver for TG synthesis [27]. In the
present study, Sch B treatment time-/dose-dependently
increased lipolysis, as evidenced by decreases in EAT
and adipocyte size. Moreover, serum NEFA level was ele-
vated after Sch B treatment, which may provide sub-
strates for endogenous TG synthesis. The same pD2
values between serum NEFA and adiposity index suggest
that the NEFA-elevating and adipose-degradating actions
of Sch B are mediated by the same enzyme (s) and/or re-
ceptor (s).
TG is the main form of lipids in liver tissue. Therefore,
hypertriglyceridemia, which is associated with an excess
accumulation of NEFA and cholesterol in liver tissue,































Fig. 6 Time response of Sch B treatment on hepatic steatosis. Experimental details were described in Fig. 1. Mice were orally administered with
Sch B (1 g/kg). Control (untreated) animals received the vehicle only. After 12, 24, 48, 72, 96, and 120 h, mice were sacrificed, and livers were removed
and frozen by liquid nitrogen. A representative microscopic picture of Oil Red O-stained liver tissue section for each group is shown in a, lipid positive
staining area of each section was computed by Image Proplus 6.0 (b). Values given are the mean ± SEM, with n = 10. *P < 0.05, **P < 0.01 vs Control,
using a one-way ANOVA followed by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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nonalcoholic steatohepatitis with or without fibrosis and
hepatocellular carcinoma [28]. In other words, NAFLD
features the entire alcohol-like spectrum of liver disease
though it is observed in the nonalcoholic, dysmetabolic
individual free of competing causes of liver disease [29].
Moreover, NEFA exhibits intrahepatic TG storage, giving
rise to lipotoxicity, which it has now become a major
public issue [30]. In the present study, a single dose of
Sch B increased serum TG level (approximately 424%)
which was accompanied with hepatomegaly, hepatic
steatosis and hepatic mitochondrial injury (i.e., hepato-
toxicity). Our previous study showed that fenofibrate, a
widely prescribed TG-lowering agent, could eliminate
Sch B- and Sch oil-induced hypertriglyceridemia, hepatic
steatosis, and liver injury [20, 31]. It has been demon-
strated that Sch B caused hepatotoxicity (increase in
serum ALT activity [19] via PI3K/AKt/mtOR signaling
pathway in our previous study [32]. We consider that
Sch B-induced hypertriglyceridemia and hepatic steatosis
resulted from the lipolysis (decrease in adipocyte size
and increase in serum NEFA) and exogenous sources
(increase in serum Apo B48). Sch B-induced hepatomeg-
aly resulted from fat accumulation and mitochondrial
damage in liver tissue. Therefore, the mouse model of
Sch B-induced hypertriglyceridemia/NAFLD (such as
nonalcoholic steatohepatitis), which manifests hypertri-
glyceridemia secondary to hepatic steatosis/steatohepati-
tis, is useful for investigating TG metabolism and
developing lipid-lowering drug. The mouse model re-
quires less time to be established, when compared with
those done by high fat diet and genetic ablation [33, 34].
As for the pathway (s) involved in Sch B-induced
hypertriglyceridemia, hepatic steatosis, and lipolysis re-
main to be studied further.
HGF, a multifunctional growth factor, is the most po-































Fig. 7 Dose response of Sch B treatment on hepatic steatosis. Experimental details were described in Figs. 1 and 6. Mice were intragastrically treated
with Sch B (0.25–2 g/kg) or vehicle. Twenty-four h later, a representative microscopic picture of Oil Red O-stained liver tissue section is shown in (a).
The lipid positive staining area of each section was computed by Image Proplus 6.0 (b). Values given are the mean ± SEM, with n = 10. *P < 0.05, **P <
0.01 vs Control, using a one-way ANOVA followed by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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been reported that HGF regulates lipid metabolism and
thus ameliorates a high-fat diet-induced fatty liver
through stimulating lipid secretion [36]. In the present
study, it was found that the time periods for the onset/
peak/recovery of Sch B-induced elevation in serum TG
levels, serum HGF levels, hepatic TG contents and hep-
atic mass were found to be 12/24/96, 24/24/120, 12/48/
120, and 12/48/>120 h post dosing, respectively. The
temporal relationships among these parameters suggest
that hepatic steatosis and hepatomegaly secondary to the
Sch B-induced increase in serum TG level may be caus-
ally related to an increase in HGF release and/or pro-
duction. In addition, the huge difference existing
between pD2 of HGF and pD2 of hepatomegaly further




























































Fig. 8 Time/dose response of Sch B treatment on hepatic mass and haematoxylin and eosin (HE) stain. Experimental details were described in Fig. 1. At
24 h after Sch B treatment, mice were sacrificed, and livers were removed and weighed to calculate the hepatic index (hepatic weight/body weight ×
100) and pharmacodynamic parameters (Emax, KD, and pD2) shown in (a and b). Then liver samples were fixed in 10% formalin and stained with HE. A
representative microscopic picture of a HE-stained liver tissue section for each group is shown in c, and total vacuole area of each section was computed
by Image Proplus 6.0 (d). Values given are the mean ± SEM, with n= 10. *P< 0.05, **P< 0.01 vs Control, using a one-way ANOVA follow by Dunnett’s
multiple comparisons test, Student’s t-test or post-hoc analysis
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suggests that the Sch B-induced elevation in serum HGF
level and hepatic mass may be mediated by different en-
zyme (s) and/or receptor (s).
Hepatic steatosis accelerates the progression of liver
injury via activation of stellate cells and pro-apoptotic
factors [37]. It also triggers the release of pro-
inflammatory cytokines, such as interleukin 1β and
tumor necrosis factor–α from hepatocytes, which pro-
mote the progression of hepatic steatosis to non-alcohol
steatohepatitis, fibrosis, and even cirrhosis [38]. In the
present study, histopathological examination revealed
that Sch B treatment caused the development of hepatic
macrovesicular steatosis, which was evidenced by the
presence of single and large fat droplets that push the
nucleus to the periphery of the hepatocyte. Moreover,
microvesicular steatosis, which is characterized by the
presence of small vesicles filling the cytoplasm of
hepatocytes, also occurred. Our previous study has
shown that serum ALT activity (an enzyme marker of
liver damage) was elevated in association with hepatic
steatosis [17], suggesting that hepatic lipid accumulation
may cause liver injury. However, there was no detectable
infiltration of inflammatory cells in the liver during the
observed time course of post-Sch B treatment. These ob-
servations might be explained in part by the apoptotic
effect produced by Sch B on Kupffer cells [32], which
play crucial roles in mediating the inflammatory pro-
cesses that promote liver injury [39]. Therefore, Sch B-
induced hepatic steatosis produces liver damage without
eliciting an inflammatory response.
Changes in the structure of hepatocyte mitochondria
were observed following the Sch B treatment. Mitochon-
dria are the organelles primarily involved in lipid oxida-



























Fig. 9 Dose response of Sch B treatment on hepatocyte structure. Experimental details were described in Fig. 1 and 8. Mice were intragastrically treated
with Sch B (0.25–2 g/kg) or vehicle. At 24 h after Sch B treatment, liver tissue sections were stained with HE (a). The total vacuole area of each section
was computed by Image Proplus 6.0 (b). Values given are the mean ± SEM, with n= 10. *P< 0.05, **P< 0.01 vs Control, using a one-way ANOVA followed
by Dunnett’s multiple comparisons test, Student’s t-test or post-hoc analysis
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derived from fatty acid and glucose metabolism. Accu-
mulating evidence has shown that hepatic mitochondrial
dysfunction is crucially involved in the pathogenesis of
NAFLD in which disturbances on lipid oxidation and
mitochondrial DNA integrity can induce lipid steatosis
and trigger apoptotic pathway, respectively [15, 40]. Hep-
atic mitochondria exhibited morphological disruption
following the Sch B treatment, wherein mitochondrial
sizes were slightly increased and cristae were disrupted,
indicative of mitochondrial structural and functional ab-
normalities that may subsequently promote the accumula-
tion of lipid vacuoles in the cytoplasm of hepatocytes.
Conclusions
In conclusion, the results obtained from the present
study indicated that Sch B treatment time-/dose-de-
pendently elevated serum and hepatic TG levels, which
were associated with increase in serum Apo B48, but not
VLDL, level. In addition, Sch B treatment markedly
reduced EAT and adipocyte size as well as increased
serum NEFA level in a time/dose-dependent manner. At
the same time, changes such as hepatomegaly, high
serum HGF level and hepatic steatosis were also ob-
served in Sch B-treated mice. Histopathological analysis
indicated that Sch B time-/dose-dependently promoted
hepatic steatosis, which may be related to mitochondrial
dysfunction in Sch B-treated mice. The ensemble of
results suggests that a mouse model of hypertriglyc-
eridemia associated hepatic steatosis and hepatotoxicity
can be established by applying a single oral dose of Sch
B. The animal model is useful for investigating lipid me-
tabolism and discovering novel lipid-lowering agents.
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72 h after Sch B treatment
120 h after Sch B treatment
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fixed in 2% glutaraldehyde Sorensen’s phosphate buffer. Then ultrathin sections were made and stained with uranyl acetate and lead citrate for TEM
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